Serum Metabolomic and Lipoprotein Profiling of Pancreatic Ductal Adenocarcinoma Patients of African Ancestry.
cholestatic (obstructive) jaundice
inflammation
lipoprotein
metabolites
pancreatic ductal adenocarcinoma
tumour stages
Journal
Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790
Informations de publication
Date de publication:
28 Sep 2021
28 Sep 2021
Historique:
received:
09
08
2021
revised:
06
09
2021
accepted:
08
09
2021
entrez:
22
10
2021
pubmed:
23
10
2021
medline:
23
10
2021
Statut:
epublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a characteristic dysregulated metabolism. Abnormal clinicopathological features linked to defective metabolic and inflammatory response pathways can induce PDAC development and progression. In this study, we investigated the metabolites and lipoproteins profiles of PDAC patients of African ancestry. Nuclear Magnetic Resonance (NMR) spectroscopy was conducted on serum obtained from consenting individuals (34 PDAC, 6 Chronic Pancreatitis, and 6 healthy participants). Seventy-five signals were quantified from each NMR spectrum. The Liposcale test was used for lipoprotein characterization. Spearman's correlation and Kapan Meier tests were conducted for correlation and survival analyses, respectively. In our patient cohort, the results demonstrated that levels of metabolites involved in the glycolytic pathway increased with the tumour stage. Raised ethanol and 3-hydroxybutyrate were independently correlated with a shorter patient survival time, irrespective of tumour stage. Furthermore, increased levels of bilirubin resulted in an abnormal lipoprotein profile in PDAC patients. Additionally, we observed that the levels of a panel of metabolites (such as glucose and lactate) and lipoproteins correlated with those of inflammatory markers. Taken together, the metabolic phenotype can help distinguish PDAC severity and be used to predict patient survival and inform treatment intervention.
Identifiants
pubmed: 34677378
pii: metabo11100663
doi: 10.3390/metabo11100663
pmc: PMC8540259
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : South African Medical Research Council
ID : N/A
Organisme : International Centre for Genetic Engineering and Biotechnology, Cape Town, South Africa
ID : N/A
Références
Analyst. 2018 Dec 3;143(24):5974-5978
pubmed: 30270368
Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):140-7
pubmed: 21098649
Eur J Surg Oncol. 2003 Sep;29(7):575-9
pubmed: 12943622
Science. 2015 Dec 11;350(6266):1391-6
pubmed: 26541605
Cell Metab. 2012 Jul 3;16(1):9-17
pubmed: 22768835
Saudi J Gastroenterol. 2019 Jan-Feb;25(1):3-13
pubmed: 30588953
Endocrinology. 2019 Jul 1;160(7):1731-1742
pubmed: 31125048
Nat Commun. 2019 Sep 25;10(1):4358
pubmed: 31554818
J Exp Clin Cancer Res. 2020 Nov 30;39(1):267
pubmed: 33256814
Endosc Ultrasound. 2017 Dec;6(Suppl 3):S76-S78
pubmed: 29387696
J Proteome Res. 2009 Jan;8(1):142-8
pubmed: 19055369
J Gen Physiol. 1927 Mar 7;8(6):519-30
pubmed: 19872213
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Int J Oncol. 2021 Feb;58(2):158-170
pubmed: 33491748
Asian Pac J Cancer Prev. 2018 Nov 29;19(11):3287-3294
pubmed: 30486639
Epidemiology. 2003 Jan;14(1):45-54
pubmed: 12500045
Appl Biochem Biotechnol. 2011 Sep;165(1):148-54
pubmed: 21505807
Clin Transl Oncol. 2005 Jun;7(5):189-97
pubmed: 15960930
Ann N Y Acad Sci. 2016 Jan;1363:91-8
pubmed: 26647078
J Med Biochem. 2020 Sep 2;39(3):283-289
pubmed: 33269016
Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11105-9
pubmed: 18678913
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Genet. 2017 Mar;49(3):367-376
pubmed: 28092686
Gastroenterol Rep (Oxf). 2020 May 27;8(4):261-276
pubmed: 32843973
Oncotarget. 2017 Aug 18;8(40):68899-68915
pubmed: 28978166
Cell Cycle. 2011 Apr 15;10(8):1271-86
pubmed: 21512313
Diabetes Metab Res Rev. 1999 Nov-Dec;15(6):412-26
pubmed: 10634967
Front Physiol. 2018 Jun 19;9:762
pubmed: 29971019
J Proteome Res. 2017 Nov 3;16(11):4208-4216
pubmed: 28937771
Oncotarget. 2016 Feb 2;7(5):5815-29
pubmed: 26735340
Cancer Res. 2012 Jan 1;72(1):356-64
pubmed: 22080567
EBioMedicine. 2020 Mar;53:102655
pubmed: 32139179
BMC Cancer. 2015 Feb 13;15:51
pubmed: 25885700
Gastroenterology. 2013 Jun;144(6):1252-61
pubmed: 23622135
Kidney Int. 2005 Mar;67(3):1142-51
pubmed: 15698456
Carcinogenesis. 2014 Jul;35(7):1441-50
pubmed: 24743516
J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210
pubmed: 30865919
J Clin Med. 2019 Nov 03;8(11):
pubmed: 31684177
Mol Cancer Res. 2017 Apr;15(4):439-447
pubmed: 28074002
Environ Health Perspect. 2003 Aug;111(10):1361-75
pubmed: 12896860
J Transl Med. 2019 Sep 14;17(1):309
pubmed: 31521169
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
World J Gastrointest Oncol. 2020 Feb 15;12(2):173-181
pubmed: 32104548
Sci Rep. 2017 Jul 24;7(1):6285
pubmed: 28740254
Pancreas. 2016 Feb;45(2):311-6
pubmed: 26646264
Metabolism. 1983 Mar;32(3):308-15
pubmed: 6828000
J Lipid Res. 2015 Mar;56(3):737-746
pubmed: 25568061
Anticancer Drugs. 2018 Apr;29(4):373-379
pubmed: 29438178
Nat Rev Cancer. 2010 Apr;10(4):267-77
pubmed: 20300106
Bioinformatics. 2017 Feb 15;33(4):621-623
pubmed: 27993774
BMJ Nutr Prev Health. 2018 Dec 5;1(1):17-22
pubmed: 33235950
Sci Rep. 2017 Dec 7;7(1):17188
pubmed: 29215048
J Proteome Res. 2021 Mar 5;20(3):1744-1753
pubmed: 33617266
Pancreas. 2015 May;44(4):522-7
pubmed: 25872128
Clin Med Res. 2007 Mar;5(1):53-60
pubmed: 17456835
Am J Surg. 2019 Dec;218(6):1206-1212
pubmed: 31514959
Cancer Treat Rev. 2013 Aug;39(5):534-40
pubmed: 22995477
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):934-947
pubmed: 31648972
Surg Clin North Am. 2010 Apr;90(2):355-64
pubmed: 20362791
Mol Med Rep. 2020 Dec;22(6):4981-4991
pubmed: 33174057
Metabolomics. 2012 Jun;8(Suppl 1):3-16
pubmed: 22593721
Cancer Metab. 2021 Aug 3;9(1):29
pubmed: 34344464
Trends Biochem Sci. 2014 Apr;39(4):191-8
pubmed: 24657017
Magn Reson Med. 1997 May;37(5):651-7
pubmed: 9126938
Gastroenterol Res Pract. 2019 Feb 4;2019:7690528
pubmed: 30863442